Candriam S.C.A. Has $7 Million Stock Holdings in Vera Therapeutics, Inc. $VERA

Candriam S.C.A. trimmed its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 18.4% during the second quarter, HoldingsChannel reports. The firm owned 296,941 shares of the company’s stock after selling 66,751 shares during the quarter. Candriam S.C.A.’s holdings in Vera Therapeutics were worth $6,996,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Vestal Point Capital LP lifted its holdings in Vera Therapeutics by 132.6% during the first quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $60,050,000 after acquiring an additional 1,425,000 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Vera Therapeutics by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock worth $114,212,000 after purchasing an additional 377,783 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Vera Therapeutics by 18.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company’s stock valued at $40,243,000 after purchasing an additional 260,188 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Vera Therapeutics during the 1st quarter valued at about $4,772,000. Finally, MPM Bioimpact LLC grew its position in shares of Vera Therapeutics by 61.3% in the 1st quarter. MPM Bioimpact LLC now owns 415,719 shares of the company’s stock valued at $9,986,000 after purchasing an additional 157,931 shares during the period. Institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on VERA shares. JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research note on Thursday, September 18th. Wolfe Research reiterated a “peer perform” rating on shares of Vera Therapeutics in a report on Monday, August 4th. Finally, Bank of America started coverage on Vera Therapeutics in a report on Thursday, October 16th. They issued a “buy” rating and a $48.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $61.90.

Vera Therapeutics Stock Down 0.1%

Vera Therapeutics stock opened at $28.35 on Friday. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.27. The company has a fifty day simple moving average of $27.97 and a 200 day simple moving average of $24.33. The company has a market cap of $1.81 billion, a P/E ratio of -7.11 and a beta of 1.22.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period in the prior year, the business posted ($0.85) EPS. Research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vera Therapeutics news, SVP Joseph R. Young sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the transaction, the senior vice president owned 47,839 shares of the company’s stock, valued at $1,390,201.34. The trade was a 23.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 16.30% of the stock is currently owned by corporate insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.